Product Transparency and Consumer Behavior: Evidence from Drug Checking
How to cite
Costello, Anna; Friedrich, Christian; Zedlitz, Gerrit von. 2025. "Product Transparency and Consumer Behavior: Evidence from Drug Checking." AEA RCT Registry. AEARCTR-0015540. https://doi.org/10.1257/rct.15540-2.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Consumer goods transactions in black markets are hampered with significant information asymmetry about product quality. This is because products are illegal and therefore unregulated, and market discipline is inefficient because competition and transparency are low. As a result, suppliers have incentives to shirk on quality, which can be particularly problematic for the trade of high risk goods. In this study, we explore the recreational drug market, where poor information about product quality can lead to acute toxicity and death. Specifically, we ask whether product-level transparency, provided through drug checking initiatives, can lead to safer drug consumption and fewer adverse health outcomes. We partner with nightclubs across Switzerland who provide drug checking stations available for patrons at their club. The drug checking booth accepts a drug that the patron has purchased and plans to consume, take a small sample of the drug, and tests and reports the exact chemical composition of the drug; this practice should largely eliminate information frictions about product quality in this high risk market. Our intervention randomly allocates drug checking "tickets" to individuals entering the club (treatment group). Due to constrained capacity of drug checking tests, we randomly decline drug checking to a control group of club patrons. We then use RFID technology to track movements throughout the club that are intended to capture drug consumption and other risky behavior. Finally, we administer a survey to club patrons to assess user experiences and behaviors. Our study seeks to assess the effectiveness of product transparency in reducing harm in the illicit drug market.
Intervention
The treatment group will receive a "ticket" (in the form of a positive RFID bracelet) that allows entry to the drug checking station. Upon seeking drug checking, the administrator will scan the bracelet to identify whether the individual is in the treatment group.
The control group will receive a control RFID bracelet, which does not allow entry to the drug checking station. Upon seeking drug checking, the administrator will scan the bracelet and inform this control group that due to capacity constraints, they will not receive drug checking on that night.
All patrons will have an RFID bracelet, allowing us to track movements of both treatment and control groups.
Experimental design
Based on the number of drug checking tests available each night, we will randomly allocate the option to take tests to a treatment group (those that receive the ability to get their drug tested) and a control group (those who will be turned down for drug checking, due to capacity constraints). We will allocate treatment at entry to the club, by handing out admission bracelets, which have been coded with an RFID chip. Randomization will be allocated based on a random number generator based on the patrons' entry order. Each patron will be made aware of the drug checking booth at entry.
At the booth, the bracelet will be checked to identify whether the patron is allowed to get their drug checked. Drugs will subsequently be checked and reported for the treatment group.
RFID technology, including antennas, will be distributed throughout the club to track movements. Movements will be captured and recorded.
At exit, patrons will be asked to take an exit survey, whereby they report their experience with drugs, consumption, and other risky behavior.
Design details
Cited by
No citation data available for this registration yet.